Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$5.60 +3.7%	$4.22	$3.21 ▼ $7.18	$1.30B	0.68	4.25 million shs	3.31 million shs
KYMR Kymera Therapeutics	$39.87 +5.8%	$44.93	$19.44 ▼ $53.27	$2.45B	2.18	595,396 shs	939,787 shs
PTGX Protagonist Therapeutics	$54.53 +1.5%	$53.95	$33.31 ▼ $60.60	$3.34B	2.33	642,141 shs	541,716 shs
SRRK Scholar Rock	$32.20 +2.4%	$35.80	$6.76 ▼ $46.98	$3.02B	0.48	1.67 million shs	1.22 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+3.65%	+23.01%	+20.27%	+59.29%	-5.26%
KYMR Kymera Therapeutics	-7.24%	-13.70%	-15.29%	+21.00%	-9.07%
PTGX Protagonist Therapeutics	+5.25%	-0.15%	+1.42%	+21.41%	+38.82%
SRRK Scholar Rock	-1.53%	-14.95%	-15.97%	+0.19%	+272.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.3447 of 5 stars	3.5	2.0	4.4	3.7	2.5	0.6
KYMR Kymera Therapeutics	2.9809 of 5 stars	4.6	3.0	0.0	0.7	2.5	0.0
PTGX Protagonist Therapeutics	2.9692 of 5 stars	3.5	3.0	0.0	3.8	2.5	0.0
SRRK Scholar Rock	4.4651 of 5 stars	4.6	1.0	4.4	1.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.00	Buy	$11.50	105.36% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	48.26% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$67.20	23.23% Upside
SRRK Scholar Rock	3.22	Buy	$45.14	40.20% Upside

Current Analyst Ratings Breakdown

Latest ARDX, PTGX, SRRK, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	PTGX Protagonist Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$67.00 ➝ $69.00
8/7/2025	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $45.00
8/6/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/5/2025	ARDX Ardelyx	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
8/5/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $12.00
8/5/2025	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00 ➝ $14.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/30/2025	SRRK Scholar Rock	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Strong-Buy	$53.00
7/17/2025	SRRK Scholar Rock	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$386.15M	3.49	N/A	N/A	$0.58 per share	9.66
KYMR Kymera Therapeutics	$47.07M	55.16	N/A	N/A	$12.90 per share	3.09
PTGX Protagonist Therapeutics	$434.43M	7.81	$4.58 per share	11.90	$10.74 per share	5.08
SRRK Scholar Rock	$33.19M	93.26	N/A	N/A	$2.43 per share	13.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.23	N/A	18.06	N/A	-14.60%	-36.57%	-13.42%	10/30/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-616.03%	-32.86%	-28.19%	10/30/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.70	77.90	N/A	N/A	24.88%	8.12%	7.41%	N/A
SRRK Scholar Rock	-$246.29M	-$2.91	N/A	N/A	N/A	N/A	-127.11%	-90.09%	N/A

Latest ARDX, PTGX, SRRK, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.83	-$0.95	-$0.12	-$0.95	$17.37 million	$11.48 million
8/6/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	-$0.55	-$0.02	-$0.55	$8.32 million	$5.55 million
8/6/2025	Q2 2025	SRRK Scholar Rock	-$0.66	-$0.98	-$0.32	-$0.98	$0.11 million	N/A
8/4/2025	Q2 2025	ARDX Ardelyx	-$0.13	-$0.08	+$0.05	-$0.08	$82.69 million	$97.66 million
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.44	4.30	4.03
KYMR Kymera Therapeutics	N/A	8.49	8.49
PTGX Protagonist Therapeutics	N/A	16.97	16.97
SRRK Scholar Rock	0.21	6.33	6.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
KYMR Kymera Therapeutics	N/A
PTGX Protagonist Therapeutics	98.63%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
KYMR Kymera Therapeutics	16.01%
PTGX Protagonist Therapeutics	4.90%
SRRK Scholar Rock	13.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	240.98 million	229.42 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
PTGX Protagonist Therapeutics	120	62.21 million	59.16 million	Optionable
SRRK Scholar Rock	140	96.13 million	83.34 million	Optionable

ARDX, PTGX, SRRK, and KYMR Headlines

Recent News About These Companies

Scholar Rock’s Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss

August 12 at 2:51 AM | msn.com

Cantor Fitzgerald Lowers Earnings Estimates for Scholar Rock

August 12 at 2:49 AM | americanbankingnews.com

Wedbush Issues Negative Forecast for Scholar Rock Earnings

August 12 at 2:29 AM | americanbankingnews.com

Analysts Offer Predictions for Scholar Rock FY2025 Earnings

August 11 at 2:49 AM | marketbeat.com

Wedbush Brokers Lower Earnings Estimates for Scholar Rock

August 11 at 2:21 AM | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Rating of "Buy" from Analysts

August 11 at 2:15 AM | marketbeat.com

XTX Topco Ltd Takes Position in Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 10 at 3:40 AM | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Q2 2025 Earnings Call Transcript

August 9 at 2:53 AM | msn.com

Scholar Rock (NASDAQ:SRRK) Stock Price Down 10.2% Following Weak Earnings

August 8, 2025 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Price Target Lowered to $45.00 at BMO Capital Markets

August 8, 2025 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Trading Down 10.2% on Disappointing Earnings

August 8, 2025 | americanbankingnews.com

Scholar Rock (NASDAQ:SRRK) Shares Gap Down on Disappointing Earnings

August 8, 2025 | americanbankingnews.com

Scholar Rock (NASDAQ:SRRK) Shares Gap Down After Earnings Miss

August 7, 2025 | marketbeat.com

Scholar Rock outlines Q3 2025 U.S. apitegromab launch plans amid regulatory progress and global expansion focus

August 7, 2025 | msn.com

Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Scholar Rock (SRRK) Q2 Loss Widens 63%

August 6, 2025 | aol.comA

Why Scholar Rock Stock Wilted on Wednesday

August 6, 2025 | fool.com

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

August 6, 2025 | businesswire.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Shares Sold by BIT Capital GmbH

August 4, 2025 | marketbeat.com

15,942 Shares in Scholar Rock Holding Corporation (NASDAQ:SRRK) Bought by Universal Beteiligungs und Servicegesellschaft mbH

August 3, 2025 | marketbeat.com

TD Asset Management Inc Sells 23,794 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX, PTGX, SRRK, and KYMR Company Descriptions

Ardelyx NASDAQ:ARDX

$5.60 +0.20 (+3.70%)

Closing price 04:00 PM Eastern

Extended Trading

$5.58 -0.01 (-0.27%)

As of 07:34 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Kymera Therapeutics NASDAQ:KYMR

$39.87 +2.19 (+5.81%)

Closing price 04:00 PM Eastern

Extended Trading

$39.84 -0.03 (-0.09%)

As of 05:48 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Protagonist Therapeutics NASDAQ:PTGX

$54.53 +0.78 (+1.45%)

Closing price 04:00 PM Eastern

Extended Trading

$54.50 -0.02 (-0.05%)

As of 07:22 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Scholar Rock NASDAQ:SRRK

$32.20 +0.74 (+2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$32.42 +0.22 (+0.70%)

As of 07:49 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time